Verrica Pharmaceuticals Inc (VRCA) Stock Price, Quote & News

Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is i...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 453 3300

Website: www.verrica.com

Address:

44 West Gay Street, Suite 400, West Chester, United States

BioGem Mar. 14 at 11:53 PM

$VRCA Shortable above 6$. Including the additional vested pre-funded warrants, they have near 21.5M shares outstanding, and the mkt cap of 130M. Too expensive with many critical negatives: -No growth QOQ of product revenue. Means adoption is poor. Generics and new at-home options are ruthless competition. -Deep operating and bottom-line losses to deepen through 2026 (expansion of sales and marketing and launching new trials). -Much lower accounts receivable and higher current liabilities now, mean a big cash burn in Q1 26. -Cash will run out before year end = Another very dilutive offering will be required.

0 · Reply

prismmarketview Mar. 12 at 1:33 PM

We've added Verrica Pharmaceuticals (NASDAQ: $VRCA) to the PRISM Pharmaceuticals Index, spotlighting its focused work in dermatology and specialty care. YCANTH is gaining solid early commercial traction, with strong 2025 revenue growth reflecting increasing adoption for molluscum contagiosum. The pipeline continues to advance meaningfully: a global Phase 3 program for common warts is underway following the first patient dosing late last year, and VP-315 is progressing in development as a potential non-surgical option for basal cell carcinoma. This addition underscores Verrica's commitment to addressing unmet needs in skin disease treatments. @VerricaPharma #Pharmaceuticals https://prismmarketview.com/companies/verrica-pharmaceuticals-inc/

0 · Reply

mikesterz7 Mar. 11 at 12:50 PM

$VRCA Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 target price.

0 · Reply

OpenOutcrier Mar. 11 at 12:49 PM

$VRCA (-10.0% pre) VRCA: Revenue growth and cost controls narrowed losses, but liquidity risks persist https://ooc.bz/l/96291

0 · Reply

StocktwitsEarnings Mar. 11 at 12:15 PM

$VRCA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.57 up 76.35% YoY • Reported revenue of $5.09M up 1380.23% YoY • Verrica Pharmaceuticals Inc. believes its $30.1M cash as of December 31, 2025, is sufficient until Q1 2027, but substantial doubt exists about its ability to continue as a going concern for one year without additional funding.

0 · Reply

ash1012 Mar. 9 at 2:04 PM

$VRCA get in now going to double this week

0 · Reply

OfficialStocktwitsUser Mar. 3 at 4:18 AM

$VRCA RSI: 27.22, MACD: -0.4845 Vol: 0.70, MA20: 6.11, MA50: 7.17 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ash1012 Mar. 2 at 3:52 PM

$VRCA WILL GO PARABOLIC ON MARCH 10TH, START LOADING

1 · Reply

BillionerOfKing Feb. 21 at 5:15 PM

$VRCA Current Stock Price: $5.78

0 · Reply

BillionerOfKing Feb. 12 at 11:46 PM

$VRCA Current Stock Price: $5.57 Contracts to trade: $2.5 VRCA Feb 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 29% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 8:00 AM EST - 11 days ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

Feb 23, 2026, 8:00 AM EST - 21 days ago

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 12, 2026, 8:00 AM EST - 4 weeks ago

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

Feb 9, 2026, 8:00 AM EST - 5 weeks ago

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Jan 7, 2026, 8:00 AM EST - 2 months ago

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

Nov 24, 2025, 8:00 AM EST - 4 months ago

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

Nov 14, 2025, 4:05 PM EST - 4 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 4 months ago

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2025, 11:00 AM EDT - 5 months ago

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 20, 2025, 4:05 PM EDT - 5 months ago

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

Oct 7, 2025, 4:05 PM EDT - 5 months ago

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 19, 2025, 8:00 AM EDT - 6 months ago

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

Jul 9, 2025, 7:00 AM EDT - 8 months ago

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

Jul 1, 2025, 7:00 AM EDT - 9 months ago

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 28, 2025, 8:00 AM EDT - 10 months ago

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 13, 2025, 4:05 PM EDT - 10 months ago

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 11 months ago

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

Apr 30, 2025, 8:00 AM EDT - 11 months ago

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

Feb 25, 2025, 4:05 PM EST - 1 year ago

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

Dec 9, 2024, 4:15 PM EST - 1 year ago

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 8:00 AM EST - 1 year ago

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Nov 21, 2024, 7:30 AM EST - 1 year ago

Verrica Announces Pricing of $42.0 Million Public Offering

Nov 20, 2024, 4:05 PM EST - 1 year ago

Verrica Announces Proposed Public Offering

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Oct 11, 2024, 5:21 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Sep 27, 2024, 10:29 PM EDT - 1 year ago

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Aug 14, 2024, 7:45 AM EDT - 1 year ago

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

Jul 1, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

May 15, 2024, 7:30 AM EDT - 1 year ago

Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

May 13, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

May 9, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

May 8, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

Apr 2, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:30 AM EDT - 2 years ago

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Feb 29, 2024, 7:30 AM EST - 2 years ago

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:30 AM EST - 2 years ago

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

BioGem Mar. 14 at 11:53 PM

0 · Reply

prismmarketview Mar. 12 at 1:33 PM

0 · Reply

mikesterz7 Mar. 11 at 12:50 PM

$VRCA Brookline Capital Acquisition upgraded shares of Verrica Pharmaceuticals from a "hold" rating to a "buy" rating and set a $17.00 target price.

0 · Reply

OpenOutcrier Mar. 11 at 12:49 PM

$VRCA (-10.0% pre) VRCA: Revenue growth and cost controls narrowed losses, but liquidity risks persist https://ooc.bz/l/96291

0 · Reply

StocktwitsEarnings Mar. 11 at 12:15 PM

0 · Reply

ash1012 Mar. 9 at 2:04 PM

$VRCA get in now going to double this week

0 · Reply

OfficialStocktwitsUser Mar. 3 at 4:18 AM

0 · Reply

ash1012 Mar. 2 at 3:52 PM

$VRCA WILL GO PARABOLIC ON MARCH 10TH, START LOADING

1 · Reply

BillionerOfKing Feb. 21 at 5:15 PM

$VRCA Current Stock Price: $5.78

0 · Reply

BillionerOfKing Feb. 12 at 11:46 PM

0 · Reply

SnipeEdge Feb. 10 at 12:58 PM

$VRCA is a biotech (Verrica Pharmaceuticals) with a dermatology treatment; commercial launch execution is critical.

0 · Reply

invisiblehand21 Feb. 3 at 9:29 PM

$VRCA hoping the iv isn't lying

0 · Reply

invisiblehand21 Feb. 3 at 8:34 PM

$VRCA i see iv 400 on good news, i buy

0 · Reply

Paper_Route_Frank Jan. 17 at 1:21 PM

$VRCA avg 9.50

0 · Reply

Lights1980 Jan. 15 at 9:42 PM

$OCGN there won’t be any PR tomorrow, but in Monday there will be a PR tha the OCU400 phase 3 study has finished dosing. We will then get an update later next week that they have sold Neocart to $VRCA

5 · Reply

StMichaelTwits Jan. 9 at 2:33 PM

$VRCA $QURE sBLA application any day with VRCA, I expect same type of move. Awesome news for QURE lead drug and so too for $CLPT support.

0 · Reply

StMichaelTwits Jan. 9 at 12:48 PM

$VRCA They have not yet released the official "Press Release" or SEC 8-K filing confirming that the sBLA (supplemental Biologics License Application) has been formally submitted. My bets, Monday or Tuesday next week!

0 · Reply

ChartChartist Jan. 8 at 8:33 PM

$VRCA this was popping up and now looking and Michael’s all over it. Good lookin, i like all this. I’ll follow your lead here. Ill be soaking up a position.

0 · Reply

StMichaelTwits Jan. 8 at 5:22 PM

$VRCA The "Silence" Period: You may notice a lack of buying in the last few weeks (late December to now). This is actually normal; insiders are often barred from trading (Blackout Period) right before a major announcement like the "imminent" BLA resubmission. Pattern Recognition: If you see a Form 4 (the SEC document for insider trades) drop immediately after the BLA is accepted, it usually signals that management believes the 60-day review will be successful. Shhh, just take it in folks.

0 · Reply

StMichaelTwits Jan. 8 at 5:16 PM

$VRCA To me, seems like screamin for approval at a home theater near you. 👇Phase 2 results "The clinically meaningful activity observed for the primary endpoint of complete clearance👈😘 in the Phase 2 COVE-1 study provides strong evidence that YCANTH has the potential to become the first therapy ever approved in both the United States and Japan for the treatment of common warts"!

0 · Reply

Market Cap	104.96M
Revenue (ttm)	7.57M
Net Income (ttm)	-76.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,011.62%
Debt to Equity Ratio	-2.00

Volume	87,800
Avg Vol	146,702
Day's Range	N/A - N/A
Shares Out	17.18M
Stochastic %K	71%
Beta	1.47
Analysts	Strong Sell
Price Target	$16.50